<scp>CD</scp>20‐positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab

Yan, Min; Dong, Zhao; Zhao, Frank; Chauncey, Thomas R.; Deauna‐Limayo, Delva; Wang‐Rodriguez, Jessica; Liu, Dayu; Wang, Huan You; Pilz, Renate B.

doi:10.1111/ejh.12286

Cited by 34 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…55 Bortezomib alone and in combination with chemotherapy has been used with limited efficacy in HIV-positive and HIV-negative patients with relapsed PBL. [56][57][58][59][60][61][62] More recently, a case series of 3 previously untreated patients with PBL, 2 of them HIV-positive, has shown efficacy with the combination of bortezomib and dose-adjusted EPOCH. 63 The immunomodulator lenalidomide induced a temporary response in a patient with relapsed PBL.…”

Section: Current Treatment Options and Emerging Therapiesmentioning

confidence: 99%

The biology and treatment of plasmablastic lymphoma

Castillo

Bibas

Miranda

2015

Blood

381

543

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with HIV infection. However, PBL can also be seen in patients with other immunodeficiencies as well as in immunocompetent individuals. Because of its distinct clinical and pathological features, such as lack of expression of CD20, plasmablastic morphology, and clinical course characterized by early relapses and subsequent chemotherapy resistance, PBL can represent a diagnostic and therapeutic challenge for pathologists and clinicians alike. Despite the recent advances in the therapy of HIV-associated and aggressive lymphomas, patients with PBL for the most part have poor outcomes. The objectives of this review are to summarize the current knowledge on the epidemiology, biology, clinical and pathological characteristics, differential diagnosis, therapy, prognostic factors, outcomes, and potential novel therapeutic approaches in patients with PBL and also to increase the awareness toward PBL in the medical community.

show abstract

Section: Current Treatment Options and Emerging Therapiesmentioning

confidence: 99%

The biology and treatment of plasmablastic lymphoma

Castillo

Bibas

Miranda

2015

Blood

381

543

View full text Add to dashboard Cite

show abstract

“…Instead, more intensive regimens such as hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine are typically used. In the very rare case that PBL expresses CD20, rituximab has been added to the chemotherapy regimen with an excellent response (10). Several groups have shown that patients with EBVpositive DLBCL have a worse prognosis when compared with patients with EBV-negative DLBCL, making EBV per se an independent adverse prognostic indicator (11).…”

Section: Discussionmentioning

confidence: 99%

Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation

Treviño

Yang

et al. 2018

View full text Add to dashboard Cite

Abstract. Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL) of the elderly is a rare subtype of B-cell neoplasms. Primary gastric EBV-positiveEBV-positive DLBCL of the elderly is characterized by higher age distribution and an aggressive clinical course with a median survival of 2 years in Asian patients. The sites of primary extranodal involvement include the skin, soft tissue, bones, nasal cavity, pharynx/hypopharynx, tonsils, tongue, lung, pleura, stomach, liver, spleen, peritoneum, cecum, and bone marrow. The neoplastic cells are of B-cell lineage, they express the pan B-cell antigens CD20 and PAX5. Plasmacytoid (or plasmablastic) cases can be CD20 weakly positive or negative, usually has an activated B-cell (ABC) immunophenotype being MUM1 positive and CD10 negative and usually BCL-6 negative. BCL-2 and CD30 are usually positive, while CD15 is negative. Ki-67 generally shows a high proliferation index. Immunoglobulin light chain restriction may be difficult to demonstrate by conventional flow cytometric analysis due to lack of surface expression of immunoglobulin light chains, except in cases with immunoblastic or plasmablastic features in which cytoplasmic immunoglobulin light chain mRNA and protein can be assessed by cytoplasmic flow cytometry or by kappa/Lambda in situ hybridization (ISH). We report a unique primary gastric EBV-positive DLBCL of the elderly with CD138 and MUM1 positive and strong immunoglobulin lambda light chain 413

show abstract

“…Several reports have documented activity of the proteasome inhibitor bortezomib in PBL [12,13,14,15,16,17]. The anti-CD30 antibody brentuximab vedotin has also been shown to have activity in 1 report [18].…”

Section: Discussionmentioning

confidence: 99%

A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy

et al. 2017

View full text Add to dashboard Cite

Background: Plasmablastic lymphoma (PBL) is an uncommon variant of diffuse large B-cell lymphoma that is characterized by its plasmacytoid features, aggressive tendencies, and frequent association with human immunodeficiency virus (HIV) infection or other immunocompromised states. Multi-agent, intensive chemotherapy regimens are recommended as first-line treatment by the National Comprehensive Cancer Network. However, the toxicity of these regimens is high and prognosis remains poor. Case Report: We report a patient with HIV-negative PBL who achieved complete response and durable remission using a lenalidomide-based chemotherapy regimen as first-line therapy. Conclusion: Cyclophosphamide, lenalidomide, dexamethasone (CRD) may provide an alternative initial therapeutic option for patients with PBL who cannot tolerate the intensive chemotherapy regimens currently recommended.

show abstract

CD20‐positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab

Cited by 34 publications

References 12 publications

The biology and treatment of plasmablastic lymphoma

The biology and treatment of plasmablastic lymphoma

Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation

A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy

Contact Info

Product

Resources

About